Hopp til hovedinnhold
Egenbehandling består i å passe godt på huden og unngå ting som kan forverre tilstanden.
Egenbehandling består i å passe godt på huden og unngå ting som kan forverre tilstanden.

Hva kan du gjøre selv?

Egenbehandling er en sentral del av behandlingen ved psoriasis. Det innebærer blant annet pleie av huden med fuktighetskrem, sol og saltvannsbad, riktig kosthold og stressmestring.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/hud/psoriasis/psoriasis-egenbehandling/ 

Fuktighetsbehandling og hudpleie

Sol og bad

Stressmestring

Kosthold

Medisiner

Vil du vite mer?

Quiz

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Psoriasis. Referanselisten for dette dokumentet vises nedenfor.

  1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. PubMed 
  2. Weigle N, McBane S. Psoriasis. Am Fam Physician 2013; 87: 626-33. PubMed 
  3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. PubMed 
  4. Armstrong AW, Mehta MD, Schupp CW,et al. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021 Jun 30. PMID: 34190957.
  5. Patrisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85. PubMed 
  6. Hoff M, Malm Gulati A, Romundstad PR, et al. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag Health Study (HUNT). Ann Rheum Dis 2015; 74: 60–64.
  7. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. PMID: 29928910. PubMed 
  8. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957-62. PubMed 
  9. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71. PubMed 
  10. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. PubMed 
  11. Zhao SS, Yiu ZZN, Barton A, Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis A Mendelian Randomization Study. JAMA Dermatol 2023. pmid:36696131 PubMed 
  12. Meffert J. Psoriasis. Medscape, last updated Apr 06, 2017. emedicine.medscape.com 
  13. Chen T-L, Lee L-L, Huang H-K, et al. Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease A Systematic Review and Meta-analysis. JAMA Dermatol 2021. pmid:34851364 PubMed 
  14. Chiricozzi A. Psoriasis. BMJ Best Practice, last updated 30 Oct 2020.
  15. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets 2006;10:817-831. PubMed 
  16. Burden-Teh E, Phillips RC, Thomas KS et al. A systematic review of diagnostic criteria for psoriasis in adults and children: evidence from studies with a primary aim to develop or validate diagnostic criteria. Br J Dermatol 2018; 178:1035–43.
  17. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol 2012; 147: 189-202. pmid:22481581 PubMed 
  18. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014 Nov. 171(5):1123-8.
  19. European Dermatology Forum. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris. Last updated 07/2020. www.edf.one 
  20. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628-36. PubMed 
  21. Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019 Jul 16;7(7):CD011972. PMID: 31309536. PubMed 
  22. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD009687. DOI: 10.1002/14651858.CD009687.pub2. DOI 
  23. Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. British Journal of Dermatology 2013; 168: 954-67. doi:10.1111/bjd.12276 DOI 
  24. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8-14. PubMed 
  25. Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011;64:936-949. PubMed 
  26. Jabbar-Lopez ZK, Wu KC, Reynolds NJ. Newer agents for psoriasis in adults. BMJ. 2014;349:g4026. doi: 10.1136/bmj.g4026. DOI 
  27. Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Europ Acad Dermatol Venereol. 2011;25(suppl 2):12-18.
  28. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Euro Acad Dermatol Venereol. 2011;25(suppl 2):19-27. PMID: 21388455. PubMed 
  29. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No.: CD011535. The Cochrane Library 
  30. Meng Y, Dongmei L, Yanbin P, et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014;39(6):696-707. doi: 10.1111/ced.12390.
  31. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etarnecept for moderate- to severe psoriasis. N Engl J Med 2010; 362: 118-28. New England Journal of Medicine 
  32. Langley RG, Elewski BE, Lebwohl MN, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371:326-338. PubMed 
  33. Hammadi AA. Psoriatic arthritis. Medscape, last updated Dec 11, 2014.
  34. Leisner MZ, Riis JL, Schwartz BS et al. Psoriasis and Risk of Mental Disorders in Denmark. JAMA Dermatol 2019.0039 pmid:31066861 PubMed 
  35. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; :CD005028. Cochrane (DOI) 
  36. Dupire G, Droitcourt C, Hughes C, Le Cleach L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD011571. DOI: 10.1002/14651858.CD011571.pub2. DOI 
  37. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(suppl 3):36-46. PMID: 23845151 PubMed 
  38. Trafford AM, Parisi R, Kontopantelis E, et al. Association of Psoriasis With the Risk of Developing or Dying of Cancer A Systematic Review and Meta-analysis. JAMA Dermatol 2019. pmid:31617868 PubMed 
  39. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-57. PubMed 
  40. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2012. doi:10.1111/j.1365-2796.2012.02593.x DOI 
  41. Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2019. pmid:31672774 PubMed 
  42. Crowley JJ, Weinberg JM, Wu JJ et al. Treatment of Nail Psoriasis. JAMA Dermatol 2015; 151(1): 87-94. pmid:25471223 PubMed 
  43. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61: 1373-8. pmid:19790120 PubMed 
  44. Feldman SR. Epidemiology, clinical manifestations, and diagnosis of psoriasis. UpToDate, last updated Dec 30, 2019. UpToDate 
  45. Sterry W, Ortonne J-P, Kirkham B. Comparison of two etanercept regimens for treatment of psoriasis and psoritaic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147. BMJ (DOI) 
  46. Paller AS, Siegfried EC, Langley RG, et al, for the Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241-51. New England Journal of Medicine